Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) – Research analysts at HC Wainwright issued their Q4 2027 earnings estimates for Viridian Therapeutics in a report released on Thursday, November 5th. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.16) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.07) per share.
Several other equities analysts have also weighed in on the company. Wells Fargo & Company lifted their price target on Viridian Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Thursday. Royal Bank Of Canada increased their price target on Viridian Therapeutics from $38.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday. Wall Street Zen downgraded Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Wedbush raised their price objective on Viridian Therapeutics from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Truist Financial boosted their price objective on Viridian Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.
Get Our Latest Research Report on Viridian Therapeutics
Viridian Therapeutics Trading Down 1.8%
VRDN stock opened at $28.55 on Friday. The company’s 50-day simple moving average is $21.88 and its 200-day simple moving average is $21.83. The company has a quick ratio of 16.95, a current ratio of 16.95 and a debt-to-equity ratio of 0.43. Viridian Therapeutics has a 52-week low of $13.18 and a 52-week high of $34.29. The firm has a market cap of $3.23 billion, a P/E ratio of -7.43 and a beta of 1.07.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 77.15%. The company had revenue of $25.75 million during the quarter, compared to analysts’ expectations of $4.72 million.
Insider Transactions at Viridian Therapeutics
In related news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 2.40% of the company’s stock.
Hedge Funds Weigh In On Viridian Therapeutics
A number of hedge funds have recently made changes to their positions in VRDN. Integrated Wealth Concepts LLC purchased a new position in shares of Viridian Therapeutics in the second quarter valued at approximately $33,000. KBC Group NV acquired a new stake in shares of Viridian Therapeutics in the first quarter worth approximately $34,000. State of Wyoming purchased a new stake in shares of Viridian Therapeutics during the second quarter worth approximately $43,000. Fulcrum Asset Management LLP purchased a new stake in shares of Viridian Therapeutics during the third quarter worth approximately $97,000. Finally, Man Group plc purchased a new stake in shares of Viridian Therapeutics during the second quarter worth approximately $197,000.
Viridian Therapeutics News Summary
Here are the key news stories impacting Viridian Therapeutics this week:
- Positive Sentiment: Q3 results beat expectations. Viridian reported a loss of $0.81 per share, narrower than analysts’ expected $1.02 loss, while revenue of $25.75 million topped the $4.72 million estimate. Shares were reported to have gapped up after the results. Q3 results and business update
- Positive Sentiment: Analysts lifted targets and reiterated bullish ratings. Leerink Partners raised its target to $54, RBC to $41, Truist to $42, and Wedbush to $42; HC Wainwright raised its target to $40 and Needham to $38. These revisions signal improved analyst expectations. Wedbush price-target update
- Positive Sentiment: Product and pipeline milestones remain in focus. Viridian is targeting broad coverage for its Lumvoa launch over the next 6–9 months and has indicated it expects to file an elegrobart biologics license application in Q1 2027. Investors are also awaiting VRDN-008 data. Lumvoa launch and elegrobart filing plans
- Neutral Sentiment: Despite the earnings beat, Viridian remains loss-making, and its quarterly loss widened compared with the year-earlier period. The beat and higher revenue may be encouraging, but sustained commercial execution and clinical progress will be important.
- Negative Sentiment: A recent commentary argued the stock may be overvalued even with its new launch, highlighting valuation as a potential headwind after the positive earnings and analyst updates. Valuation commentary
Viridian Therapeutics Company Profile
Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.
Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.
Featured Stories
- Five stocks we like better than Viridian Therapeutics
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
